

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40L.USPT,PGPB.	664
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1799
CD40S	0
LIGAND.USPT,PGPB.	52101
LIGANDS.USPT,PGPB.	42671
FUSION.USPT,PGPB.	84832
FUSIONS.USPT,PGPB.	10679
PROTEIN.USPT,PGPB.	138960
PROTEINS.USPT,PGPB.	115218
IG.USPT,PGPB.	14726
((CD40L OR CD40 ADJ LIGAND) SAME (FUSION ADJ PROTEIN) SAME (IG OR IMMUNOGLOBULIN)).USPT,PGPB.	57

[There are more results than shown above. Click here to view the entire set.](#)

**Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L3

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

**DATE:** Thursday, March 27, 2003   [Printable Copy](#)   [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

*DB=USPT,PGPB; PLUR=YES; OP=ADJ*L3 (cd40L or cd40 adj ligand) same (fusion adj protein) same (ig or immunoglobulin)57 L3L2 L1.clm.15 L2L1 (cd40L or cd40 adj ligand) same (fusion adj protein)137 L1

END OF SEARCH HISTORY

**Set Name Query**

side by side

**Hit Count Set Name**

result set

*DB=USPT,PGPB; PLUR=YES; OP=ADJ*L3 (cd40L or cd40 adj ligand) same (fusion adj protein) same (ig or immunoglobulin)57 L3L2 L1.clm.15 L2L1 (cd40L or cd40 adj ligand) same (fusion adj protein)137 L1

END OF SEARCH HISTORY



Generate Collection

L3: Entry 42 of 57

File: USPT

Aug 22, 2000

DOCUMENT-IDENTIFIER: US 6106832 A

TITLE: Treatment of individuals exhibiting defective CD40L

Brief Summary Text (12):

The present invention further provides a method of treating an individual that has a syndrome in which the interaction of T cells and B cells is affected (such as X-linked hyper-IgM syndrome), comprising administering an effective amount of a soluble CD40L. Soluble forms of CD40L comprise the extracellular region of CD40L, and include, for example, fusion proteins comprising the extracellular region of CD40L and an Fc region of a human immunoglobulin, and CD40L multimers formed by adding a multimer-forming peptide to the extracellular region of CD40L.

## CLAIMS:

2. The method of claim 1, wherein the soluble, oligomeric CD40 ligand comprises a fusion protein selected from the group consisting of the extracellular region of CD40 ligand and an Fc region of a human immunoglobulin, and a fusion protein formed by adding a multimer-forming peptide to the extracellular region of CD40L.

8. The method of claim 7 wherein the soluble, oligomeric CD40L comprises a fusion protein selected from the group consisting of the extracellular region of CD40 ligand and an Fc region of a human immunoglobulin, and a fusion protein formed by adding a multimer-forming peptide to the extracellular region of CD40L.



Generate Collection

L3: Entry 41 of 57

File: USPT

Jul 24, 2001

DOCUMENT-IDENTIFIER: US 6264951 B1

TITLE: Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L

Detailed Description Text (132):

These data indicate that the interaction of CD40 with its ligand is the principal molecular interaction responsible for T cell contact dependent induction of B cell growth and differentiation to both antigen-specific antibody production and polyclonal Ig secretion. As such, these data suggest that antagonists of this interaction, by soluble CD40, CD40/Fc fusion protein and possibly soluble CD40-L (monomeric), will significantly interfere with development of antibody responses. Therefore clinical situations where CD40, CD40/Fc fusion proteins and soluble CD40-L are suitable include allergy, lupus, rheumatoid arthritis, insulin dependent diabetes mellitus, and any other diseases where autoimmune antibody or antigen/antibody complexes are responsible for clinical pathology of the disease. Moreover, membrane-bound CD40-L or oligomeric soluble CD40-L will be useful to stimulate B cell proliferation and antibody production. As such, these forms of CD40-L are most useful for vaccine adjuvants and as a stimulating agent for mAb secretion from hybridoma cells.

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40L.USPT,PGPB.	664
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1799
CD40S	0
LIGAND.USPT,PGPB.	52101
LIGANDS.USPT,PGPB.	42671
FUSION.USPT,PGPB.	84832
FUSIONS.USPT,PGPB.	10679
PROTEIN.USPT,PGPB.	138960
PROTEINS.USPT,PGPB.	115218
IG.USPT,PGPB.	14726
((CD40L OR CD40 ADJ LIGAND) SAME (FUSION ADJ PROTEIN) SAME (IG OR IMMUNOGLOBULIN)).USPT,PGPB.	57

There are more results than shown above. [Click here to view the entire set.](#)

**Database:**

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L3

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

**DATE:** Thursday, March 27, 2003   [Printable Copy](#)   [Create Case](#)